Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 1 (2004), Issue 2 (December)

1. Making protein interactions druggable: targeting PDZ domains.
   Nat Rev Drug Discov, 3(12): 1047-56. [Abstract] [Full-text]
2. Strategies to overcome resistance to targeted protein kinase inhibitors.
   Nat Rev Drug Discov, 3(12): 1001-10. [Abstract] [Full-text]
3. Emergency department crowding and thrombolysis delays in acute myocardial infarction.
   Ann Emerg Med, 44(6): 577-85. [Abstract] [Full-text]
4. HIV status of sexual partners is more important than antiretroviral treatment related perceptions for risk taking by HIV positive MSM in Montreal, Canada.
   Sex Transm Infect, 80(6): 518-23. [Abstract] [Full-text]
5. Comparing the quality of antidepressant pharmacotherapy in the Department of Veterans Affairs and the private sector.
   Psychiatr Serv, 55(12): 1386-91. [Abstract] [Full-text]
6. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
   Eur Neuropsychopharmacol, 15(1): 111-7. [Abstract] [Full-text]
7. Adaptive inhibitors of the HIV-1 protease.
   Prog Biophys Mol Biol, 88(2): 193-208. [Abstract] [Full-text]
8. Attitudes and perceptions of nurses and doctors to nurse-led and nurse-initiated thrombolysis--an Irish perspective.
   Eur J Cardiovasc Nurs, 3(4): 303-13. [Abstract] [Full-text]
9. The ubiquitin system: pathogenesis of human diseases and drug targeting.
   Biochim Biophys Acta, 1695(1): 3-17. [Abstract] [Full-text]
10. Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone.
    Int J Gynecol Cancer, 14(6): 1112-7. [Abstract] [Full-text]
11. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?
    J Am Geriatr Soc, 52(12): 2082-7. [Abstract] [Full-text]
12. Clinical implications of ST-segment non-resolution after thrombolysis for myocardial infarction.
    J R Soc Med, 97(12): 566-70. [Abstract] [Full-text]
13. 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid, a small molecule isocoumarin, potentiates dexamethasone-induced apoptosis of human multiple myeloma cells.
    Cancer Res, 64(23): 8512-6. [Abstract] [Full-text]
14. Chemotherapy error reduction: a multidisciplinary approach to create templated order sets.
    J Pediatr Oncol Nurs, 22(1): 20-30. [Abstract] [Full-text]
15. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report.
    Pediatrics, 114(6): 1601-5. [Abstract] [Full-text]
16. The use of cell-penetrating peptides for drug delivery.
    Drug Discov Today, 9(23): 1012-9. [Abstract] [Full-text]
17. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy.
    Clin Infect Dis, 39(12): 1852-5. [Abstract] [Full-text]
18. Functional outcomes following chemoradiotherapy for head and neck cancer.
    Otolaryngol Head Neck Surg, 131(6): 950-7. [Abstract] [Full-text]
19. Direct round window application of gentamicin with varying delivery vehicles: a comparison of ototoxicity.
    Otolaryngol Head Neck Surg, 131(6): 890-6. [Abstract] [Full-text]
20. Tumid lupus erythematosus occurring following highly active antiretroviral therapy for HIV infection: a manifestation of immune restoration.
    J Am Acad Dermatol, 51(5): S161-5. [Abstract] [Full-text]
21. Designing information technology to support prescribing decision making.
    Qual Saf Health Care, 13(6): 450-4. [Abstract] [Full-text]
22. Efficacy of penicillin for dental pain without overt infection.
    Acad Emerg Med, 11(12): 1268-71. [Abstract] [Full-text]
23. DNA encapsulated magnesium and manganous phosphate nanoparticles: potential non-viral vectors for gene delivery.
    Biomaterials, 26(14): 2157-63. [Abstract] [Full-text]
24. The use of chitosan as a condensing agent to enhance emulsion-mediated gene transfer.
    Biomaterials, 26(14): 2147-56. [Abstract] [Full-text]
25. Size and temperature effects on poly(lactic-co-glycolic acid) degradation and microreservoir device performance.
    Biomaterials, 26(14): 2137-45. [Abstract] [Full-text]
26. Self-gelling hydrogels based on oppositely charged dextran microspheres.
    Biomaterials, 26(14): 2129-35. [Abstract] [Full-text]
27. Synthesis and characterization of the paclitaxel/MPEG-PLA block copolymer conjugate.
    Biomaterials, 26(14): 2121-8. [Abstract] [Full-text]
28. Physically crosslinked alginate/N,O-carboxymethyl chitosan hydrogels with calcium for oral delivery of protein drugs.
    Biomaterials, 26(14): 2105-13. [Abstract] [Full-text]
29. Synthesis and drug release behavior of poly (trimethylene carbonate)-poly (ethylene glycol)-poly (trimethylene carbonate) nanoparticles.
    Biomaterials, 26(14): 2089-94. [Abstract] [Full-text]
30. Silver ion release from antimicrobial polyamide/silver composites.
    Biomaterials, 26(14): 2081-8. [Abstract] [Full-text]
31. Novel biomaterials for bisphosphonate delivery.
    Biomaterials, 26(14): 2073-80. [Abstract] [Full-text]
32. Polymers incorporating nitric oxide releasing/generating substances for improved biocompatibility of blood-contacting medical devices.
    Biomaterials, 26(14): 1685-93. [Abstract] [Full-text]
33. New vehicle based on a microemulsion for topical ocular administration of dexamethasone.
    Clin Experiment Ophthalmol, 32(6): 626-32. [Abstract] [Full-text]
34. Glaucoma treatment in Australia: changing patterns of therapy 1994-2003.
    Clin Experiment Ophthalmol, 32(6): 590-6. [Abstract] [Full-text]
35. Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study.
    J Gastroenterol, 39(11): 1095-101. [Abstract] [Full-text]
36. Safety in training and learning in the intensive care unit.
    Crit Care Clin, 21(1): 129-48, ix. [Abstract] [Full-text]
37. Medication safety and transfusion errors in the ICU and beyond.
    Crit Care Clin, 21(1): 91-110, ix. [Abstract] [Full-text]
38. Failure mode and effects analysis application to critical care medicine.
    Crit Care Clin, 21(1): 21-30, vii. [Abstract] [Full-text]
39. Defining and measuring patient safety.
    Crit Care Clin, 21(1): 1-19, vii. [Abstract] [Full-text]
40. HIV dementia: an evolving disease.
    J Neuroimmunol, 157(1): 3-10. [Abstract] [Full-text]
41. Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy.
    Clin Endocrinol (Oxf), 61(6): 760-7. [Abstract] [Full-text]
42. A prospective randomized crossover study of the preemptive analgesic effect of nitrous oxide in oral surgery.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 98(6): 637-42. [Abstract] [Full-text]
43. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases.
    Curr Opin Struct Biol, 14(6): 716-30. [Abstract] [Full-text]
44. Drug therapy in the elderly.
    Exp Gerontol, 39(11): 1731-8. [Abstract] [Full-text]
45. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment.
    Ophthalmology, 111(12): 2232-9. [Abstract] [Full-text]
46. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression.
    Ophthalmology, 111(12): 2224-31. [Abstract] [Full-text]
47. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma.
    Gynecol Oncol, 95(3): 762-4. [Abstract] [Full-text]
48. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study.
    Gynecol Oncol, 95(3): 695-700. [Abstract] [Full-text]
49. Neoadjuvant high-dose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration in patients with stages IIIa-IVa cervical cancer.
    Gynecol Oncol, 95(3): 576-82. [Abstract] [Full-text]
50. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.
    Gynecol Oncol, 95(3): 539-45. [Abstract] [Full-text]
51. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group.
    Gynecol Oncol, 95(3): 496-9. [Abstract] [Full-text]
52. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
    Gynecol Oncol, 95(3): 469-73. [Abstract] [Full-text]
53. pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol.
    Clin Cancer Res, 10(23): 8085-93. [Abstract] [Full-text]
54. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors.
    Clin Cancer Res, 10(23): 8048-58. [Abstract] [Full-text]
55. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
    Clin Cancer Res, 10(23): 8005-17. [Abstract] [Full-text]
56. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses.
    Clin Cancer Res, 10(23): 7994-8004. [Abstract] [Full-text]
57. Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV).
    Clin Cancer Res, 10(23): 7934-40. [Abstract] [Full-text]
58. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
    Clin Cancer Res, 10(23): 7896-902. [Abstract] [Full-text]
59. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
    Clin Cancer Res, 10(23): 7884-95. [Abstract] [Full-text]
60. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial.
    Clin Cancer Res, 10(23): 7860-4. [Abstract] [Full-text]
61. A novel method of cocaine delivery to fruit flies using a graphic arts airbrush.
    J Neurosci Methods, 141(1): 89-96. [Abstract] [Full-text]
62. Radiation synthesis of interpolymer polyelectrolyte complex and its application as a carrier for colon-specific drug delivery system.
    Biomaterials, 26(15): 2733-9. [Abstract] [Full-text]
63. Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes.
    Biomaterials, 26(15): 2723-32. [Abstract] [Full-text]
64. An investigation on the physicochemical properties of chitosan/DNA polyelectrolyte complexes.
    Biomaterials, 26(15): 2705-11. [Abstract] [Full-text]
65. Adsorption of a therapeutic enzyme to self-assembled monolayers: effect of surface chemistry and solution pH on the amount and activity of adsorbed enzyme.
    Biomaterials, 26(15): 2695-704. [Abstract] [Full-text]
66. Development of functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells.
    Biomaterials, 26(15): 2685-94. [Abstract] [Full-text]
67. Nanocrystalline hydroxyapatite and calcium sulphate as biodegradable composite carrier material for local delivery of antibiotics in bone infections.
    Biomaterials, 26(15): 2677-84. [Abstract] [Full-text]
68. Ectopic bone formation associated with recombinant human bone morphogenetic proteins-2 using absorbable collagen sponge and beta tricalcium phosphate as carriers.
    Biomaterials, 26(15): 2501-7. [Abstract] [Full-text]
69. Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals.
    Atherosclerosis, 178(1): 165-72. [Abstract] [Full-text]
70. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light.
    Transfusion, 44(12): 1732-40. [Abstract] [Full-text]
71. BANs to rINNS.
    J Clin Pharm Ther, 29(6): 491-5. [Abstract] [Full-text]
72. Predictive performance of 'Diprifusor' TCI system in patients during upper abdominal surgery under propofol/fentanyl anesthesia.
    J Zhejiang Univ Sci B, 6(1): 43-8. [Abstract] [Full-text]
73. Alternating weekly administration of paclitaxel and gemcitabine: a phase II study in patients with advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol, 55(2): 152-8. [Abstract] [Full-text]
74. Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo.
    Cancer Immunol Immunother, 54(2): 120-8. [Abstract] [Full-text]
75. Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients.
    Clin Pharmacol Ther, 76(6): 639-47. [Abstract] [Full-text]
76. Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.
    Am J Obstet Gynecol, 191(6): 1921-7. [Abstract] [Full-text]
77. Heterogeneous microcirculation in the rat small intestine during hemorrhagic shock: quantification of the effects of hypertonic-hyperoncotic resuscitation.
    Eur Surg Res, 36(6): 338-44. [Abstract] [Full-text]
78. Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma.
    Onkologie, 27(6): 540-4. [Abstract] [Full-text]
79. Secondary surgical cytoreduction for advanced ovarian carcinoma.
    N Engl J Med, 351(24): 2489-97. [Abstract] [Full-text]
80. Model study of AREDS antioxidant supplementation of AMD compared to Visudyne: a dominant strategy?
    Ophthalmic Epidemiol, 11(5): 337-46. [Abstract] [Full-text]
81. Adjusting insulin doses: from knowledge to decision.
    Patient Educ Couns, 56(1): 98-103. [Abstract] [Full-text]
82. Preferences regarding medical and psychosocial support in HIV-infected patients.
    Patient Educ Couns, 56(1): 16-20. [Abstract] [Full-text]
83. Nitric oxide in postmenopausal women taking three different HRT regimens.
    Maturitas, 50(1): 52-7. [Abstract] [Full-text]
84. Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women.
    Maturitas, 50(1): 19-29. [Abstract] [Full-text]
85. Hormone replacement therapy in the menopause. Structure and content of risk talk.
    Maturitas, 50(1): 8-18. [Abstract] [Full-text]
86. A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer.
    Int J Radiat Oncol Biol Phys, 60(5): 1494-501. [Abstract] [Full-text]
87. Hormones, menopause, and heart disease: making sense of the Women's Health Initiative.
    Womens Health Issues, 14(6): 212-9. [Abstract] [Full-text]
88. Preparation of 100 nm diameter unilamellar vesicles containing zinc phthalocyanine and cholesterol for use in photodynamic therapy.
    Chem Phys Lipids, 133(1): 69-78. [Abstract] [Full-text]
89. Future therapy of diabetes mellitus.
    Biomed Pharmacother, 58(10): 578-81. [Abstract] [Full-text]
90. Local, non-viral IL-12 gene therapy using a water soluble lipopolymer as carrier system combined with systemic paclitaxel for cancer treatment.
    J Control Release, 101(1): 273-85. [Abstract] [Full-text]
91. Polymer genomics: shifting the gene and drug delivery paradigms.
    J Control Release, 101(1): 259-71. [Abstract] [Full-text]
92. Cationic polymethacrylates with covalently linked membrane destabilizing peptides as gene delivery vectors.
    J Control Release, 101(1): 233-46. [Abstract] [Full-text]
93. Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles.
    J Control Release, 101(1): 223-32. [Abstract] [Full-text]
94. Biodegradable polymersomes as a basis for artificial cells: encapsulation, release and targeting.
    J Control Release, 101(1): 187-98. [Abstract] [Full-text]
95. Controlled release of proteins from degradable poly(ether-ester) multiblock copolymers.
    J Control Release, 101(1): 175-86. [Abstract] [Full-text]
96. Mapping neutral microclimate pH in PLGA microspheres.
    J Control Release, 101(1): 163-73. [Abstract] [Full-text]
97. Transmucosal macromolecular drug delivery.
    J Control Release, 101(1): 151-62. [Abstract] [Full-text]
98. The role of branched polyesters and their modifications in the development of modern drug delivery vehicles.
    J Control Release, 101(1): 137-49. [Abstract] [Full-text]
99. Dual growth factor delivery from degradable oligo(poly(ethylene glycol) fumarate) hydrogel scaffolds for cartilage tissue engineering.
    J Control Release, 101(1): 111-25. [Abstract] [Full-text]
100. The production of protein-loaded microparticles by supercritical fluid enhanced mixing and spraying.
     J Control Release, 101(1): 85-92. [Abstract] [Full-text]
101. Hydrotropic polymer micelle system for delivery of paclitaxel.
     J Control Release, 101(1): 59-68. [Abstract] [Full-text]
102. Rational design of composition and activity correlations for pH-sensitive and glutathione-reactive polymer therapeutics.
     J Control Release, 101(1): 47-58. [Abstract] [Full-text]
103. Tailor-made polymers for local drug delivery: release of macromolecular model drugs from biodegradable hydrogels based on poly(ethylene oxide).
     J Control Release, 101(1): 13-20. [Abstract] [Full-text]
104. Vinorelbine plus low-dose cisplatinum with concomitant radiotherapy for the treatment of locally advanced or inoperable non-metastasized non-small-cell lung cancer (stage I-IIIB): a phase II study.
     Radiother Oncol, 73(3): 321-4. [Abstract] [Full-text]
105. Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy.
     AIDS Res Hum Retroviruses, 20(11): 1196-209. [Abstract] [Full-text]
106. Human immunodeficiency virus type 1 infection in Oman: antiretroviral therapy and frequencies of drug resistance mutations.
     AIDS Res Hum Retroviruses, 20(11): 1166-72. [Abstract] [Full-text]
107. HAART-prolonged life of HIV-infected patients should not be shortened by hepatitis C.
     Infection, 32(6): 369-71. [Abstract] [Full-text]
108. Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer.
     Urology, 64(6): 1231.e1-3. [Abstract] [Full-text]
109. Povidone iodine and dextrose solution combination sclerotherapy in chyluria.
     Urology, 64(6): 1107-9; discussion 1110. [Abstract] [Full-text]
110. Drug localization and targeting with receptor microscopic autoradiography.
     J Pharmacol Toxicol Methods, 51(1): 25-40. [Abstract] [Full-text]
111. Molecular therapeutic target for type-2 diabetes.
     J Proteome Res, 3(6): 1284-8. [Abstract] [Full-text]
112. Molecular evaluation of ablative therapy of Barrett's oesophagus.
     J Pathol, 205(1): 57-64. [Abstract] [Full-text]
113. Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy.
     Diabetologia, 47(11): 1895-905. [Abstract] [Full-text]
114. Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience.
     Ann Oncol, 16(1): 146-51. [Abstract] [Full-text]
115. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly).
     Ann Oncol, 16(1): 124-31. [Abstract] [Full-text]
116. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
     Ann Oncol, 16(1): 116-23. [Abstract] [Full-text]
117. Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer.
     Ann Oncol, 16(1): 97-101. [Abstract] [Full-text]
118. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.
     Ann Oncol, 16(1): 81-9. [Abstract] [Full-text]
119. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study.
     Ann Oncol, 16(1): 75-80. [Abstract] [Full-text]
120. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
     Ann Oncol, 16(1): 64-9. [Abstract] [Full-text]
121. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.
     Ann Oncol, 16(1): 56-63. [Abstract] [Full-text]
122. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens.
     Ann Oncol, 16(1): 7-15. [Abstract] [Full-text]
123. What has happened to antimicrobial usage in primary care in the United Kingdom since the SMAC report? - description of trends in antimicrobial usage using the General Practice Research Database.
     J Public Health (Oxf), 26(4): 359-64. [Abstract] [Full-text]
124. Relationships between age, drugs, oral sensorial complaints and salivary profile.
     Arch Oral Biol, 50(1): 7-16. [Abstract] [Full-text]
125. Assessing associations between medication adherence and potentially modifiable psychosocial variables in pediatric kidney transplant recipients and their families.
     Pediatr Transplant, 8(6): 543-50. [Abstract] [Full-text]
126. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials.
     Trop Med Int Health, 9(12): 1241-6. [Abstract] [Full-text]
127. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
     Gynecol Oncol, 96(1): 198-203. [Abstract] [Full-text]
128. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
     Gynecol Oncol, 96(1): 168-72. [Abstract] [Full-text]
129. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
     Gynecol Oncol, 96(1): 132-5. [Abstract] [Full-text]
130. Role of pegylated liposomal doxorubicin in ovarian cancer.
     Gynecol Oncol, 96(1): 10-8. [Abstract] [Full-text]
131. Coexistence of treatment-related MLL cleavage and rearrangement in a child with haemophagocytic lymphohistiocytosis.
     Br J Cancer, 91(12): 1990-2. [Abstract] [Full-text]
132. Public health vaccination policies for containing an anthrax outbreak.
     Nature, 432(7019): 901-4. [Abstract] [Full-text]
133. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
     J Natl Cancer Inst, 96(24): 1823-31. [Abstract] [Full-text]
134. Continuous subcutaneous insulin infusion in neonatal diabetes mellitus.
     Pediatr Diabetes, 5(4): 202-6. [Abstract] [Full-text]
135. Drug related critical incidents.
     Anaesthesia, 60(1): 48-52. [Abstract] [Full-text]
136. HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.
     Cancer Res, 64(24): 9144-51. [Abstract] [Full-text]
137. Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.
     Cancer Res, 64(24): 9115-23. [Abstract] [Full-text]
138. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
     Cancer Res, 64(24): 9105-14. [Abstract] [Full-text]
139. Adaptive bolus-based targeted glucose regulation of hyperglycaemia in critical care.
     Med Eng Phys, 27(1): 1-11. [Abstract] [Full-text]
140. Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
     Lung Cancer, 47(1): 121-7. [Abstract] [Full-text]
141. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
     Lung Cancer, 47(1): 111-20. [Abstract] [Full-text]
142. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial.
     Lung Cancer, 47(1): 103-9. [Abstract] [Full-text]
143. Adjuvant chemotherapy for radically resected non-small cell lung cancer: a retrospective analysis of 311 consecutively treated patients.
     Lung Cancer, 47(1): 93-101. [Abstract] [Full-text]
144. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.
     Lung Cancer, 47(1): 69-80. [Abstract] [Full-text]
145. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines.
     Lung Cancer, 47(1): 31-9. [Abstract] [Full-text]
146. The use of total lymphocyte count (TLC) as an independent criterion for initiating HAART in resource-poor countries.
     J Infect, 50(1): 66-7. [Abstract] [Full-text]
147. Controlled release of plasmid DNA from photo-cross-linked pluronic hydrogels.
     Biomaterials, 26(16): 3319-26. [Abstract] [Full-text]
148. Self-curing controlled release systems for steroids. Application of prednisolone-based polymeric systems to ear diseases.
     Biomaterials, 26(16): 3311-8. [Abstract] [Full-text]
149. Fabrication and characterization of a smart drug delivery system: microsphere in hydrogel.
     Biomaterials, 26(16): 3299-309. [Abstract] [Full-text]
150. Sleep apnea and hormone replacement therapy: a pilot study and a literature review.
     Acta Obstet Gynecol Scand, 84(1): 54-7. [Abstract] [Full-text]
151. 16alpha-Bromoepiandrosterone restores T helper cell type 1 activity and accelerates chemotherapy-induced bacterial clearance in a model of progressive pulmonary tuberculosis.
     J Infect Dis, 191(2): 299-306. [Abstract] [Full-text]
152. Bambuí Project: a qualitative approach to self-medication.
     Cad Saude Publica, 20(6): 1661-9. [Abstract] [Full-text]
153. Effect of self-medication with antimalarial drugs on malaria infection in pregnant women in South-Western Nigeria.
     Med Princ Pract, 14(1): 6-9. [Abstract] [Full-text]
154. Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.
     Chemotherapy, 50(6): 289-96. [Abstract] [Full-text]
155. EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.
     Adv Otorhinolaryngol, 62: 81-91. [Abstract] [Full-text]
156. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age.
     J Neurol Neurosurg Psychiatry, 76(1): 103-5. [Abstract] [Full-text]
157. The interventional therapy of varicoceles amongst children, adolescents and young men.
     Eur J Radiol, 53(1): 46-56. [Abstract] [Full-text]
158. Illicit use of prescription pain medication among college students.
     Drug Alcohol Depend, 77(1): 37-47. [Abstract] [Full-text]
159. LC-MS/MS determination in rabbit plasma of the main photoproduct of RLP068/Cl, a cationic sensitizer proposed for photodynamic therapy (PDT) of microbial infections.
     J Chromatogr B Analyt Technol Biomed Life Sci, 814(1): 133-41. [Abstract] [Full-text]
160. A survey of anti-fungal management in lung transplantation.
     J Heart Lung Transplant, 23(12): 1376-81. [Abstract] [Full-text]
161. SRL172 (killed Mycobacterium vaccae) may augment the efficacy of trastuzumab in metastatic breast cancer patients.
     Med Hypotheses, 64(2): 248-51. [Abstract] [Full-text]
162. The relationship between HAART use and employment for HIV-positive individuals: an empirical analysis and policy outlook.
     Health Policy, 71(2): 255-64. [Abstract] [Full-text]
163. Development of an HPLC method for monitoring of Photofrin II therapy.
     Clin Biochem, 38(1): 73-8. [Abstract] [Full-text]
164. Swellable drug-polyelectrolyte matrices (SDPM). Characterization and delivery properties.
     Int J Pharm, 288(1): 87-99. [Abstract] [Full-text]
165. Hyaluronan-based microspheres as tools for drug delivery: a comparative study.
     Int J Pharm, 288(1): 35-49. [Abstract] [Full-text]
166. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
     Br J Haematol, 128(1): 49-58. [Abstract] [Full-text]
167. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome.
     Br J Dermatol, 151(6): 1204-12. [Abstract] [Full-text]
168. Photodynamic therapy with verteporfin in patients with age-related macular degeneration and juxtafoveal choroidal neovascularization.
     Acta Ophthalmol Scand, 82(6): 651-5. [Abstract] [Full-text]
169. Encouraging results of photodynamic therapy with Visudyne in a clinical patient material of age-related macular degeneration.
     Acta Ophthalmol Scand, 82(6): 645-50. [Abstract] [Full-text]
170. National Prescribing Service: creating an implementation arm for national medicines policy.
     Br J Clin Pharmacol, 59(1): 112-6. [Abstract] [Full-text]
171. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation.
     Aliment Pharmacol Ther, 20(11): 1289-96. [Abstract] [Full-text]
172. Adverse drug events caused by medication errors in medical inpatients.
     Swiss Med Wkly, 134(45): 664-70. [Abstract] [Full-text]
173. Rational targeting for prion therapeutics.
     Nat Rev Neurosci, 6(1): 23-34. [Abstract] [Full-text]
174. Compartment syndrome after thrombolysis for acute myocardial infarction.
     Emerg Med J, 22(1): 77. [Abstract] [Full-text]
175. Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare.
     J Clin Oncol, 22(24): 4966-70. [Abstract] [Full-text]
176. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
     J Clin Oncol, 22(24): 4958-65. [Abstract] [Full-text]
177. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
     J Clin Oncol, 22(24): 4926-33. [Abstract] [Full-text]
178. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.
     J Clin Oncol, 22(24): 4901-6. [Abstract] [Full-text]
179. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.
     J Clin Oncol, 22(24): 4888-92. [Abstract] [Full-text]
180. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma.
     J Clin Oncol, 22(24): 4881-7. [Abstract] [Full-text]
181. Bullous pemphigoid associated with mantle cell lymphoma.
     Arch Dermatol, 140(12): 1496-9. [Abstract] [Full-text]
182. Sensitization of tumor cells toward chemotherapy: enhancing the efficacy of camptothecin with imidazolines.
     Chem Biol, 11(12): 1689-99. [Abstract] [Full-text]
183. Concordance between clopidogrel use and prescribing guidelines.
     Intern Med J, 34(12): 663-7. [Abstract] [Full-text]
184. In vivo gene delivery of urokinase-type plasminogen activator with regulatable lentivirus induces behavioural changes in chronic cocaine administration.
     Eur J Neurosci, 20(12): 3473-88. [Abstract] [Full-text]
185. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline.
     J Clin Oncol, 22(24): 4979-90. [Abstract] [Full-text]
186. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
     Clin Infect Dis, 40(1): 174-81. [Abstract] [Full-text]
187. Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy.
     Clin Infect Dis, 40(1): 167-73. [Abstract] [Full-text]
188. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.
     Clin Infect Dis, 40(1): 158-63. [Abstract] [Full-text]
189. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort.
     Clin Infect Dis, 40(1): 148-57. [Abstract] [Full-text]
190. A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site.
     Jpn J Clin Oncol, 34(11): 681-5. [Abstract] [Full-text]
191. Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment.
     Jpn J Clin Oncol, 34(11): 667-72. [Abstract] [Full-text]
192. Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study.
     Jpn J Clin Oncol, 34(11): 654-9. [Abstract] [Full-text]
193. Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study.
     Jpn J Clin Oncol, 34(11): 647-53. [Abstract] [Full-text]
194. HIV+ MALT lymphoma remission induced by highly active antiretroviral therapy alone.
     Eur J Haematol, 74(1): 70-2. [Abstract] [Full-text]
195. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
     Eur J Haematol, 74(1): 40-6. [Abstract] [Full-text]
196. Evaluation of drug interaction software to identify alerts for transplant medications.
     Ann Pharmacother, 39(1): 45-50. [Abstract] [Full-text]
197. The impact of new drug introduction on drug expenditure in primary health care in Catalunya, Spain.
     Ann Pharmacother, 39(1): 177-82. [Abstract] [Full-text]
198. Oedema formation in experimental photo-irradiation therapy of brain tumours using 5-ALA.
     Acta Neurochir (Wien), 147(1): 57-65; discussion 65. [Abstract] [Full-text]
199. Chemoradiotherapy as a bladder-preservation approach for muscle-invasive bladder cancer: current status and perspectives.
     Int J Clin Oncol, 9(6): 484-90. [Abstract] [Full-text]
200. Chemoradiotherapy for brain tumors: current status and perspectives.
     Int J Clin Oncol, 9(6): 471-4. [Abstract] [Full-text]
201. Chemoradiotherapy for uterine cancer: current status and perspectives.
     Int J Clin Oncol, 9(6): 458-70. [Abstract] [Full-text]
202. Chemoradiotherapy for pancreatic cancer: current status and perspectives.
     Int J Clin Oncol, 9(6): 451-7. [Abstract] [Full-text]
203. Chemoradiotherapy for esophageal cancer: current status and perspectives.
     Int J Clin Oncol, 9(6): 444-50. [Abstract] [Full-text]
204. Chemoradiotherapy for lung cancer: current status and perspectives.
     Int J Clin Oncol, 9(6): 435-43. [Abstract] [Full-text]
205. Chemoradiotherapy for head and neck cancer: current status and perspectives.
     Int J Clin Oncol, 9(6): 421-34. [Abstract] [Full-text]
206. Rationale for chemoradiotherapy.
     Int J Clin Oncol, 9(6): 414-20. [Abstract] [Full-text]
207. Photodynamic therapy with PhotoPoint photosensitiser MV6401, indium chloride methyl pyropheophorbide, achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris.
     Br J Ophthalmol, 89(1): 113-9. [Abstract] [Full-text]
208. Better medication management for Aboriginal people with mental health disorders: a survey of providers.
     Aust J Rural Health, 12(6): 253-7. [Abstract] [Full-text]
209. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
     Eur J Cancer, 41(1): 81-92. [Abstract] [Full-text]
210. High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol.
     Eur J Cancer, 41(1): 71-80. [Abstract] [Full-text]
211. Blinding decreased recruitment in a prevention trial of postmenopausal hormone therapy.
     J Clin Epidemiol, 57(12): 1237-43. [Abstract] [Full-text]
212. Methods to assess intended effects of drug treatment in observational studies are reviewed.
     J Clin Epidemiol, 57(12): 1223-31. [Abstract] [Full-text]
213. Clinical benefits of hydration and volume expansion in a wide range of illnesses may be attributable to reduction of sympatho-vagal ratio.
     Med Hypotheses, 64(3): 646-50. [Abstract] [Full-text]
214. Improved drug delivery to cancer cells: a method using magnetoliposomes that target epidermal growth factor receptors.
     Med Hypotheses, 64(3): 468-70. [Abstract] [Full-text]
215. Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
     Cancer Chemother Pharmacol, 55(3): 271-6. [Abstract] [Full-text]
216. Can a commercial diagnostic ultrasound device accelerate thrombolysis? An in vitro skull model.
     Stroke, 36(1): 124-8. [Abstract] [Full-text]
217. Morbidity of adjuvant hepatic arterial infusion pump chemotherapy in the management of colorectal cancer metastatic to the liver.
     Am J Surg, 188(6): 714-21. [Abstract] [Full-text]
218. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial).
     Am J Cardiol, 95(1): 113-6. [Abstract] [Full-text]
219. Intravascular ultrasound assessment of neointima distribution and the length of stent that was free of intravascular ultrasound-detectable intimal hyperplasia in paclitaxel-eluting stents.
     Am J Cardiol, 95(1): 107-9. [Abstract] [Full-text]
220. Comparison of quantitative angiographic parameters with the magnitude of neointimal hyperplasia measured by volumetric intravascular ultrasound in patients treated with bare metal and nonpolymeric paclitaxel-coated stents.
     Am J Cardiol, 95(1): 105-7. [Abstract] [Full-text]
221. Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis.
     Am J Cardiol, 95(1): 100-1. [Abstract] [Full-text]
222. Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests.
     Cancer, 103(1): 191-9. [Abstract] [Full-text]
223. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma.
     Cancer, 103(1): 22-31. [Abstract] [Full-text]
224. Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma.
     Cancer, 103(1): 52-8. [Abstract] [Full-text]
225. Human herpesvirus 8-negative malignant effusion lymphoma: a distinct clinical entity and successful treatment with rituximab.
     Leuk Lymphoma, 46(3): 415-9. [Abstract] [Full-text]
226. Long-term survival of patients with resistant lymphoma treated with tandem stem cell transplant.
     Leuk Lymphoma, 46(3): 405-14. [Abstract] [Full-text]
227. Acute myeloid leukemia in the elderly: etoposide when anthracyclins are contraindicated.
     Leuk Lymphoma, 46(3): 401-4. [Abstract] [Full-text]
228. Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group (E1993).
     Leuk Lymphoma, 46(3): 377-85. [Abstract] [Full-text]
229. Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine.
     Leuk Lymphoma, 46(3): 367-75. [Abstract] [Full-text]
230. In vivo and in vitro treatment of HTLV-1 and HTLV-2 infected cells with arsenic trioxide and interferon-alpha.
     Leuk Lymphoma, 46(3): 347-55. [Abstract] [Full-text]
231. Sequential application of chemotherapy and monoclonal CD 20 antibody: successful treatment of advanced composite-lymphoma.
     Leuk Lymphoma, 46(2): 285-8. [Abstract] [Full-text]
232. Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL).
     Leuk Lymphoma, 46(2): 233-8. [Abstract] [Full-text]
233. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART).
     Leuk Lymphoma, 46(2): 207-15. [Abstract] [Full-text]
234. A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma.
     Leuk Lymphoma, 46(2): 197-206. [Abstract] [Full-text]
235. Rapid pleurodesis in symptomatic malignant pleural effusion.
     Eur J Cardiothorac Surg, 27(1): 19-22. [Abstract] [Full-text]
236. Liposome-encapsulated actin-hemoglobin (LEAcHb) artificial blood substitutes.
     Biomaterials, 26(17): 3759-69. [Abstract] [Full-text]
237. Pharmacologically active microcarriers: a tool for cell therapy.
     Biomaterials, 26(17): 3727-37. [Abstract] [Full-text]
238. In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery.
     Int J Pharm, 288(2): 361-8. [Abstract] [Full-text]
239. Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems.
     Int J Pharm, 288(2): 325-34. [Abstract] [Full-text]
240. Solid lipid micro-particles carrying insulin formed by solvent-in-water emulsion-diffusion technique.
     Int J Pharm, 288(2): 281-8. [Abstract] [Full-text]
241. Plasma enhanced chemical vapor depositions to encapsulate crystals in thin polymeric films: a new approach to controlling drug release rates.
     Int J Pharm, 288(2): 253-61. [Abstract] [Full-text]
242. Enhancement of topical delivery of drugs via direct penetration by reducing blood flow rate in skin.
     Int J Pharm, 288(2): 227-33. [Abstract] [Full-text]
243. Triblock copolymers: synthesis, characterization, and delivery of a model protein.
     Int J Pharm, 288(2): 207-18. [Abstract] [Full-text]
244. Analysis of pyrazine 2,5-dipropionic acid in 5-aminolevulinic acid-loaded urological and topical delivery vehicles: methodology and assay validation.
     J Pharm Biomed Anal, 36(5): 1099-105. [Abstract] [Full-text]
245. Prophylaxis of sternal wound infections with gentamicin-collagen implant: randomized controlled study in cardiac surgery.
     J Hosp Infect, 59(2): 108-12. [Abstract] [Full-text]
246. Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy.
     Soc Psychiatry Psychiatr Epidemiol, 40(1): 72-7. [Abstract] [Full-text]
247. A longitudinal analysis of unmet need for oral treatment in a national sample of medical HIV patients.
     Am J Public Health, 95(1): 73-5. [Abstract] [Full-text]
248. Understanding and addressing AIDS-related stigma: from anthropological theory to clinical practice in Haiti.
     Am J Public Health, 95(1): 53-9. [Abstract] [Full-text]
249. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
     Clin Cancer Res, 10(24): 8656-64. [Abstract] [Full-text]
250. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.
     Clin Cancer Res, 10(24): 8641-7. [Abstract] [Full-text]
251. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
     Clin Cancer Res, 10(24): 8486-92. [Abstract] [Full-text]
252. Differential effects of delivery of omega-3 fatty acids to human cancer cells by low-density lipoproteins versus albumin.
     Clin Cancer Res, 10(24): 8275-83. [Abstract] [Full-text]
253. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant.
     Clin Cancer Res, 10(24): 8170-6. [Abstract] [Full-text]
254. Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.
     Clin Cancer Res, 10(24): 8147-51. [Abstract] [Full-text]
255. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome.
     Biol Blood Marrow Transplant, 11(1): 65-73. [Abstract] [Full-text]
256. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
     Biol Blood Marrow Transplant, 11(1): 13-22. [Abstract] [Full-text]
257. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).
     J Clin Oncol, 23(1): 190-6. [Abstract] [Full-text]
258. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
     J Clin Oncol, 23(1): 142-53. [Abstract] [Full-text]
259. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
     J Clin Oncol, 23(1): 105-12. [Abstract] [Full-text]
260. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
     J Clin Oncol, 23(1): 79-87. [Abstract] [Full-text]
261. In vivo endothelial interaction between ACE and COX inhibitors.
     Prostaglandins Leukot Essent Fatty Acids, 72(2): 129-31. [Abstract] [Full-text]
262. Inefficient central nervous system delivery limits the use of ibuprofen in neurodegenerative diseases.
     Eur J Pharm Sci, 24(1): 101-5. [Abstract] [Full-text]
263. Influence of probenecid on the delivery of morphine-6-glucuronide to the brain.
     Eur J Pharm Sci, 24(1): 49-57. [Abstract] [Full-text]
264. Collagen-chondroitin sulfate-based PLLA-SAIB-coated rhBMP-2 delivery system for bone repair.
     Biomaterials, 26(18): 4023-34. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.